Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China
December 21, 2020 02:00 ET
|
Allecra Therapeutics GmbH; Shanghai Haini Pharmaceutical Co., Ltd.
Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development...
Iterum Therapeutics Reports First Quarter 2020 Financial Results
May 14, 2020 06:45 ET
|
Iterum Therapeutics plc
--Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 -- -- Raised $51.6 million through a private placement with new and existing investors -- DUBLIN,...
Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)
March 31, 2020 07:00 ET
|
Iterum Therapeutics plc
Topline results from uUTI and cUTI clinical trials to be announced in Q2 2020 Iterum Therapeutics maintaining business operations amid COVID-19 public health crisis DUBLIN, Ireland and CHICAGO,...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
March 12, 2020 06:45 ET
|
Iterum Therapeutics plc
--Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1----NDAs anticipated to file with the FDA in mid-2020-- DUBLIN, Ireland and CHICAGO, March 12, 2020 ...
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infection
December 26, 2019 17:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection
November 18, 2019 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Reports Third Quarter 2019 Financial Results and Highlights
November 12, 2019 16:30 ET
|
Iterum Therapeutics plc
--Phase 3 topline data from the cIAI trial expected shortly-- --cUTI and uUTI Phase 3 trials remain on track to complete enrollment around year-end and report topline data in Q1 2020-- -- NDA...
Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
September 27, 2019 16:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Reports Second Quarter 2019 Financial Results
August 14, 2019 07:00 ET
|
Iterum Therapeutics plc
--Phase 3 Topline Data anticipated in the fourth quarter-- -- NDA filings expected in first quarter of 2020-- DUBLIN, Ireland and CHICAGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
Iterum Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
August 01, 2019 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...